The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections
Rilpivirine (RPV, R278474) was highlighted in 2005, two years after the death of Dr. Paul Janssen, as the ideal non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV infections. For this purpose, it was subsequently combined with tenofovir disoproxil fumarate (TDF), tenofovir alafenami...
Saved in:
| Main Author: | Erik De Clercq |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/17/7/959 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation
by: Serena Spampinato, et al.
Published: (2025-06-01) -
Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinics
by: Katerina A. Christopoulos, et al.
Published: (2024-11-01) -
Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study
by: Diana Hernández-Sánchez, et al.
Published: (2025-07-01) -
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA) [version 1; peer review: 2 approved]
by: Fafa Addo Boateng, et al.
Published: (2025-03-01) -
Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data
by: Yiyang Liu, et al.
Published: (2025-02-01)